503A pharmacies vs 503B outsourcing facilities
Released: · Last reviewed:
A 503A compounding pharmacy is state-licensed and compounds for individual patients pursuant to prescriptions, overseen mainly by state boards of pharmacy. A 503B outsourcing facility is FDA-registered, may compound larger batches under cGMP, and is subject to FDA inspection. Neither status makes any compounded product FDA approved — licensing and registration are facility statuses, not product approvals, and no pharmacy is ever "FDA approved" or "FDA licensed."
503A compounding pharmacy
- Compounds for identified patients pursuant to prescriptions
- Primary oversight: state board of pharmacy, USP standards
- Not registered with FDA as a manufacturer
- Products are not FDA approved
503B outsourcing facility
- May compound larger batches, within legal limits, without patient-specific prescriptions
- FDA registration, cGMP requirements, FDA inspections
- Registration is a facility status, renewed annually
- Products are still not FDA approved
Why this matters when choosing a GLP-1 program
Providers often cite "FDA-registered 503B facility" as a quality signal. The oversight difference is real — cGMP and FDA inspection are meaningful — but the phrase is routinely misread as product approval, which it is not. A 503A pathway is not inherently inferior either; it is the lawful route for patient-specific compounding. Whichever type a provider claims, verify the specific facility: confirm 503B claims against FDA's registered outsourcing-facility list and 503A licenses against the state board, using the four-step verification workflow. Our tracked-facility statuses live in the pharmacy records database.
Frequently asked questions
What is the difference between a 503A pharmacy and a 503B outsourcing facility?
A 503A pharmacy compounds a drug for a named patient's prescription under state board oversight, while a 503B outsourcing facility registers with FDA, follows federal manufacturing (CGMP) rules and can make batches without patient-specific prescriptions; neither status makes the compounded drug FDA-approved. FDA proposed on April 30, 2026 (91 FR 23431) not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list; comments closed July 30, 2026, and no final decision had been published by October 15, 2026. NexLife's plan pages name 503A pharmacies only.